We use cookies to understand how you use our site and to improve your experience. This includes personalizing content and advertising. To learn more, click here. By continuing to use our site, you accept our use of cookies. Cookie Policy.

Features Partner Sites Information LinkXpress hp
Sign In
Advertise with Us
PURITAN MEDICAL

Download Mobile App




e-Incubator Technology Provides Real-Time Imaging of Bioengineered Tissues in a Controlled Unit

By LabMedica International staff writers
Posted on 24 Nov 2014
A new e-incubator, an innovative miniature incubator that is compatible with magnetic resonance imaging (MRI), enables scientists to grow tissue-engineered constructs under a controlled setting and to study their growth and development in real time without risk of contamination or damage. More...


Offering the potential to test engineered tissues before human transplantation increases the success rate of implantation, and accelerates the translation of tissue engineering methods from the lab to the clinic, the novel e-incubator was described in the journal Tissue Engineering, Part C.

Shadi Othman, PhD, Karin Wartella, PhD, Vahid Khalilzad Sharghi, and Huihui Xu, PhD, from the University of Nebraska-Lincoln (USA), presented their findings of a validation study using the device to culture tissue-engineered bone constructs for four weeks. The e-incubator is a standalone unit that automatically detects and regulates internal conditions such as temperature, carbon dioxide levels, and pH via a microcontroller. It performs media exchange to feed the cultures and remove waste products. The current design is compatible with MRI to monitor the constructs without removing them from the incubator. With proper adjustments, compatibility with other imaging technologies including computed tomography [CT] and optical imaging is also possible.”

“Calibratable, hands-free tissue development environments are becoming increasingly important for the engineering of implantable tissues,” said Tissue Engineering co-editor-in-chief Peter C. Johnson, MD, vice president, research and development, Avery Dennison Medical Solutions (Chicago, IL, USA), and president and CEO, Scintellix, LLC (Raleigh, NC, USA). “In this new development, noninvasive imaging modalities are added to the spectrum of sensing and environmental capabilities that heretofore have included temperature, humidity, light, physical force, and electromagnetism. This represents a solid advance for the field.”

Related Links:

University of Nebraska-Lincoln



Gold Member
Neonatal Heel Incision Device
Tenderfoot
Online QC Software
Acusera 24•7
Automated Coagulation Analyzer
Hemolumi H6
HPV Test
Allplex HPV28 Detection
Read the full article by registering today, it's FREE! It's Free!
Register now for FREE to LabMedica.com and get access to news and events that shape the world of Clinical Laboratory Medicine.
  • Free digital version edition of LabMedica International sent by email on regular basis
  • Free print version of LabMedica International magazine (available only outside USA and Canada).
  • Free and unlimited access to back issues of LabMedica International in digital format
  • Free LabMedica International Newsletter sent every week containing the latest news
  • Free breaking news sent via email
  • Free access to Events Calendar
  • Free access to LinkXpress new product services
  • REGISTRATION IS FREE AND EASY!
Click here to Register








Channels

Molecular Diagnostics

view channel
Image Credit: Shutterstock

Fully Automated Test Advances Hepatitis D Diagnosis and Monitoring

Hepatitis D virus infection can accelerate progression to cirrhosis and liver cancer, making timely diagnosis and longitudinal monitoring essential. Because hepatitis D depends on co-infection or superinfection... Read more

Hematology

view channel
Image Credit: Shutterstock

New Biomarkers Predict Resistance to Targeted Therapy in Rare Blood Cancer

Blastic plasmacytoid dendritic cell neoplasm (BPDCN) is a rare and aggressive leukemia with limited treatment options and a poor prognosis. Although tagraxofusp is the first approved targeted therapy for... Read more

Immunology

view channel
Image:Proteomic tear-fluid analysis revealed abnormal patterns in proteins that regulate nerves and T cells in individuals with eye problems (Image Credit: Adobe Stock)

Diagnostic Models Detect Hidden Eye Abnormalities After Mild COVID-19

Persistent ocular symptoms after COVID-19 can severely affect reading, work, and daily tasks, yet standard eye exams often reveal no clear abnormalities. Patients experiencing photophobia, eye pain, and... Read more

Industry

view channel
Photo courtesy of Natera

Natera’s Signatera Earns IVDR Certification for Solid Tumor MRD Testing

Natera’s Signatera has received certification as a Class C device under the European Union’s In Vitro Diagnostic Regulation (IVDR), becoming the first personalized MRD test for solid tumors to achieve... Read more
Copyright © 2000-2026 Globetech Media. All rights reserved.